drugset
drugset / Trial / NCT03284164

Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex

NCT03284164 ↗

Phase 1 Completed 16 enrolled ContraVir Pharmaceuticals, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase 1 study to investigate the effects of Renal Impairment on the pharmacokinetics of Tenofovir exalidex

Timeline

Start
2017-09-28
Primary completion
2018-01-17
Completion
2018-02-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenofovir Exalidex Other / unclassified — —

Indications

impaired renal function disease